These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21105109)

  • 1. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Ratziu V; Caldwell S; Neuschwander-Tetri BA
    Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
    Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin sensitizers in nonalcoholic steatohepatitis.
    Harrison SA; Schenker S; Cusi K
    Hepatology; 2011 Apr; 53(4):1404-5; author reply 1405. PubMed ID: 21480350
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?
    Bugianesi E; Zannoni C; Vanni E; Marzocchi R; Marchesini G
    Dig Liver Dis; 2004 Mar; 36(3):165-73. PubMed ID: 15046183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
    Chavez-Tapia NC; Barrientos-Gutierrez T; Tellez-Avila FI; Sanchez-Avila F; Montano-Reyes MA; Uribe M
    World J Gastroenterol; 2006 Dec; 12(48):7826-31. PubMed ID: 17203528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing insulin resistance in Type 1 diabetes.
    Pang TT; Narendran P
    Diabet Med; 2008 Sep; 25(9):1015-24. PubMed ID: 19183305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones.
    Wong AK; Struthers AD; Choy AM; Lang CC
    Heart Fail Clin; 2012 Oct; 8(4):539-50. PubMed ID: 22999238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N; Hatzitolios AI
    Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
    Lonardo A; Bellentani S; Ratziu V; Loria P
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):279-89. PubMed ID: 21476922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
    Adams LA; Angulo P
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1059-60. PubMed ID: 15625648
    [No Abstract]   [Full Text] [Related]  

  • 20. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.